:format(jpeg):focal(3924x1906:3934x1896)/cloudfront-us-east-1.images.arcpublishing.com/gfrmedia/2PA3WMBILBEVNOOAJSJFEMNNII.jpg)
“Lung cancer is the leading cause of cancer-related deaths. cancer andn all over the world and its mortality rate is the highest among both men and women,” highlights the World Health Organization (WHO).
There are two main types of lung cancer: non-small cell or non-microcytic, which accounts for approximately 85% of cases, and small cell or microcytic, more aggressive but less common. “The term ‘small cell’ refers to the size and shape of the cancer cells seen under the microscope,” clarify the specialists from the Spanish Society of Medical Oncology (SEOM).
The disease goes through different phases. Stage I is considered a tumor smaller than three centimeters that has not spread to the lymph nodes or other organs. Stage II occurs when the tumor has spread to the nearest lymph nodes. In stage III it has reached lymph nodes far from the tumor or has invaded other nearby non-pulmonary tissues, for example, the vessels in the space between the two lungs, the heart or the esophagus. Finally, stage IV implies that the tumor has metastasized to other organs in the body. “The most common are the brain, bones, adrenal glands, the opposite lung and the liver,” detail the doctors at the University of Navarra Clinic.
In the case of non-small cell lung cancer, which is the most common, in stages I, II and in selected cases of stage III, the treatment chosen by oncologists is usually surgery. “The objective is the total removal of the lung tumor and the lymph nodes near the tumor, as well as those in the mediastinum” (the space between the two lungs), point out SEOM specialists. “The affected lobe or lobes can be removed but, sometimes, it is necessary to remove the entire lung,” they emphasize.
After surgery, when the tumor has been analyzed and it has been proven whether the lymph nodes are affected or not, the medical team decides whether to give chemotherapy. SEOM oncologists explain that, on some occasions, chemotherapy is used before surgery with the intention of reducing the size of the tumor.
Precisely, The most recent milestone in immunotherapy is its use together with chemotherapy before surgery, since it increases patients’ chances of cureexplains Dr. Manuel Cobo in the presentation “The great potential of immunotherapy in the treatment of lung cancer”, delivered at the XIV Congress of the Spanish Society of Thoracic Surgery (SECT), which was recently held in Malaga (south of Spain). Manuel Cobo is a medical oncologist at the Regional University Hospital of Malaga and member of the oncological committee that evaluates the potential of immunotherapy treatment in this hospital.
One of the reasons malignant cells are successful in growing is because they are able to hide from the immune system. Treatment with immunotherapy causes the immune system to identify tumor cells as a foreign agent that must be attacked. “Immunotherapy removes the barrier that prevents the immune system from attacking tumor cells. They are monoclonal antibodies that help in the function of recognizing tumor cells and destroying them,” says Dr. Cobo.
After its emergence, immunotherapy has led to a total change of paradigms in non-small cell lung cancer, as a second-line treatment, when platinum-based chemotherapy, used as a first-line treatment, fails. In these cases, “immunotherapy has been a ‘boom’ and we have seen how some tumors began to respond, with a long-term survival of between 10% and 12% of patients with metastatic lung cancer, when before immunotherapy was rare for them to last longer than two years,” says the oncologist.
Furthermore, immunotherapy is administered alone and as a first-line treatment in cases of metastatic non-small cell lung cancer when the overexposure of the PD-L1 biomarker is more than 50% in the tumor cells. If the presence of this biomarker is less than 50%, the standard treatment is chemotherapy and immunotherapy.
Likewise, it is used as a standard of treatment in stage III, when the tumor is not operable. Previously, in these cases the standard treatment was the combination of chemotherapy and radiotherapy. Currently, chemotherapy and radiotherapy continue to be used and, at the end, immunotherapy is administered for one year as maintenance treatment so that the lung cells do not progress to cancer again.
But The most notable novelty regarding immunotherapy is its application in patients with non-small cell lung cancer who end up being operable after receiving chemotherapy and immunotherapy before surgery. According to data from the Spanish Society of Thoracic Surgery (SECT), this strategy increases the probability that a patient will be cured after five years by between 15% and 20%.
“It is clear that with immunotherapy the probability of more long-term lung cancer patients surviving increases. Even in cases of metastatic lung cancer, the tumor can disappear. The addition of immunotherapy to chemotherapy increases the chances that there will be more long-term surviving patients, that is, that they will be able to undergo surgery, receive a complete treatment and, therefore, be cured, when before they relapsed after two years,” highlights the Dr. Cobo.
“When we consider long-term survival, at 5 years, 15% of patients treated with immunotherapy are still alive and will not die immediately. We only look at what has happened at this cut-off point, but the majority of these patients will live beyond that time, they will be able to heal and have a life with their natural potential,” adds the doctor.
The specialist clarifies that “of the drugs in the immunotherapy spectrum, only PD-L1 biomarker inhibitors increase long-term survival and cure rates in any stage of non-small cell lung cancer.”
Currently, there are several lines of open research that explore the great potential of immunotherapy in the treatment of cancer. “The future lies in improving the cure rate by developing new drugs from the immunological and non-immunological spectrum,” assesses the oncologist.
